What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?
about
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazineLow dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapsesRole of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazineCombined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis.New developments in the treatment of inflammatory bowel disease.Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis.Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gammaTherapeutic strategies for the management of ulcerative colitis.Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine.Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy.Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis.
P2860
Q24685766-91CDDD89-6DAB-42A5-9027-E0749ADC3AF5Q28205383-922EC07D-F5F4-4471-8B97-B26A714ACBA4Q33628518-1966EB07-05C4-4087-99B6-9210A3DB08C2Q34425918-DA4A2FEF-0551-4E94-895E-62C32F2241BEQ34517160-38C387F3-5D55-4DCF-B03A-3605314C47C1Q34544666-33551384-6767-445E-BB5D-6C095B5E14DDQ35354681-B325FF9D-BF9A-4700-9D47-2405827E330AQ35361187-0665684C-4EE8-4709-8E98-BD47057D85DFQ35719665-09A584FB-A339-46A9-9B69-39BD6AC48508Q36403491-0BD4B8D2-1148-4DAC-9AFB-004F3011278FQ37318035-99536D9D-E046-430A-B08D-2C5140A56302Q37859277-EF72490E-7F18-497C-8D2C-646843D97067Q43687351-F4CC5732-C5C6-4F04-9E02-C6641858346DQ43714774-DC9EFE40-FE7A-4D6D-9A38-EEA0018334C9Q44786115-067E7A39-8D7B-481D-BD97-DB856F51481A
P2860
What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?
@en
type
label
What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?
@en
prefLabel
What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?
@en
P2860
P356
P1433
P1476
What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?
@en
P2093
P2860
P304
P356
10.1136/GUT.42.6.761
P407
P577
1998-06-01T00:00:00Z